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Abstract
Polyphenols are naturally derived bioactive compounds with numerous reported health benefits. We have previously reported on the
beneficial effect of a polyphenol-enriched apple extract in a murine model of food allergy. The objectives of the present study were to
elucidate the class of bioactive polyphenols that exhibit a beneficial anti-allergic effect and to assess whether the protective effect matches
the in vivo bioavailable metabolite concentrations. Female BALB/c mice were sensitised to ovalbumin (OVA) following the protocol of a
well-established murine model of food allergy. They were fed diets containing polyphenol-enriched extracts or purified epicatechin for
8 d after the last sensitisation. The sensitised mice were orally challenged with OVA after the intervention. The allergy symptoms, in addition
to allergen-specific serum Ig concentrations and gene expression profiles in the intestine, of the control and treated mice were compared.
Plasma samples were collected to compare the concentrations of bioavailable epicatechin metabolites in the treatment groups. Polyphenol-
enriched fruit extracts containing epicatechin exhibited a significant anti-allergic effect in vivo. This effect was unambiguously attributed to
epicatechin, as oral administration of this purified polyphenol to sensitised mice by inclusion in their diet modulated allergy symptoms in
a dose-dependent manner. Immune parameters were also affected by the administration of epicatechin. Bioavailability measurements in
plasma indicated that the attenuation of allergy symptoms could be due to the higher concentrations of bioavailable epicatechin metabolites.
In conclusion, epicatechin is a key bioactive polyphenol that has the ability to modulate allergy outcomes in sensitised mice.
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The epidemic rise in the incidence of allergic disorders over
the last two decades has prompted the search for therapeutic
approaches that can mitigate allergic manifestations(1–3). Diet-
ary ingredients such as probiotics, prebiotics and polyphenols
have emerged as possible interventions with the potential to
minimise the development of allergy symptoms in sensitised
individuals(4–6). Polyphenols, in particular, represent a broad
family of about 5000 compounds that are found in abundance
in our daily diet as various plant-derived food products(7).
Polyphenols have been demonstrated to confer multiple
health benefits ranging from their effects on the cardiovascular
system(8) to those exerted due to their anti-diabetic(9) and anti-
inflammatory properties(10,11). Different polyphenol-enriched
extracts have been evaluated for their anti-allergy benefits
in pre-clinical models and clinical trial settings, where they
have been shown to either affect allergic sensitisation or
inhibit allergy symptoms during allergen re-exposure(12–17).
However, the majority of studies conducted in the field have
not used well-characterised polyphenol-enriched plant or fruit
extracts at varying doses to demonstrate a beneficial health
effect. These extracts contain numerous bioactive classes of
polyphenols at a range of concentrations. In addition, very
few studies dealing with allergic disorders have investigated
the specific class of bioactive polyphenols and the required
dosage to mediate a protective effect in pre-clinical or clinical
settings.
To further build on these scientific observations, in the pre-
sent study, we aimed to (1) identify the bioactive component
in beneficial polyphenol-enriched extracts and determine the
effective dose that confers in vivo benefits; (2) examine the
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impact of polyphenols on immunological events that dictate
the sequelae of allergic responses, in particular, at the site of
local inflammatory; and (3) establish a robust methodology
to detect bioavailable metabolites whose presence matches
the in vivo anti-allergic effect and subsequently investigate
how these metabolites themselves affect the immune
response(6). Herein, we report that epicatechin is one of the key
bioactive polyphenols mediating the observed anti-allergic
effect. Epicatechin is a well-studied polyphenol belonging to
the flavanol (flavan-3-ol) class of polyphenols that is abundantly
present in cocoa, green tea and certain species of apples(18–23).
We also report for the first time that epicatechin exhibits in vivo
efficacy for mitigating clinical symptoms in an ovalbumin
(OVA)-induced murine model of food allergy.
Materials and methods
Ovalbumin food allergy model
The OVA food allergy model has been described pre-
viously(16,24). Briefly, 6-week-old conventional female BALB/
c OlaHsd mice (10–15 animals per group) (Harlan Labora-
tories) were sensitised via the oral route daily during the
first 3 d and then at weekly intervals with 20 mg of OVA
(Sigma) along with 10mg/mouse of cholera toxin used as an
adjuvant (List Biological Laboratories) for a continuous
period of 7 weeks. Different polyphenol-enriched apple
extracts (1 % included in the diet: extract A – Diana Naturals;
extract B – Evesse apple extract manufactured by Coressence
Limited and kindly supplied by Danisco-Dupont), a poly-
phenol-enriched cocoa extract (6 % included in the diet,
obtained from Monteloeder) or purified epicatechin (1, 0·3
and 0·01 % included in the diet; Sigma) were mixed with
powdered mouse chow pellets (Kliba Nafga), packaged in
50 g sachets and fed to the sensitised mice for 8 d (at the
end of the sensitisation phase: days 42–49) (schematic
representation shown in Fig. 1(a)). New sachets of the pre-
pared diet were used to feed the mice daily and the amount
of diet left at the end of the day was measured. Negative
control (sensitisation with cholera toxin alone) and positive
control (given the regular diet) groups of mice were included
in the experiments to ascertain the efficacy of the treatments.
The polyphenol content of the original mouse diet was also
verified to minimise the effect of confounding variables in
the experiments; no epicatechin was detected in the originally
sourced mouse chow pellets. After the treatment period, all
the sensitised mice were exposed to an oral challenge of
100 mg OVA. Starting 30 min after the challenge, the mice
were individually observed for 30 min for allergic clinical
symptoms. The allergy symptom score was calculated as fol-
lows: 0, no symptoms; 1, four to ten episodes of scratching
around the nose and head and no diarrhoea; 2, more than
ten episodes of scratching or presence of soft stools; 3, more
than ten episodes of scratching and presence of soft stools
or diarrhoea; 4, diarrhoea in combination with immobility,
bristled fur, laboured respiration or cyanosis; 5, anaphylaxis.
Any animal achieving a score of 4 in the experiments was
immediately killed for ethical reasons. The mice were killed
4 h after the challenge, and blood, mesenteric lymph nodes,
and segments from the last few centimetres of the ileum and
jejunum were isolated and stored for further analysis. All investi-
gators who performed the scoring were blinded during
symptom evaluation, organ harvesting and subsequent in vitro
cell-culture assays. All experiments were approved by the
Nestec Internal Ethics Committee and the Service Ve´te´rinaire
of the Canton of Vaud, Switzerland (Authorisation no. 1970·1).
Analysis of the polyphenol composition of apple extracts
The polyphenol composition of the extracts used in the pre-
sent study was analysed by HPLC as described previously(25).
The polyphenol classes evaluated were flavonoids, mainly
flavonols (catechin, epicatechin and procyanidins) and
dihydrochalcones (phloridzin).
Quantitative determination of gene expression levels by
real-time PCR (low-density arrays)
Total RNA were extracted from the ileal samples using the SV
Total RNA Isolation System Kit (Promega) according to the man-
ufacturer’s protocol. RNA was quantified using the Quant-IT
Ribogreen Reagent Kit obtained from Promega according to
the manufacturer’s protocol. Reverse transcription was carried
out on 1mg of total RNA using the Multiscribe Reverse Tran-
scriptase Kit obtained from Applied Biosystems. Total RNA
was mixed with 50mM of random hexamers, 0·5 mM of deoxy-
nucleotide triphosphates (dNTP), 20 U of RNase inhibitor
(Applied Biosystems), 62·5 U of Multiscribe Reverse Transcrip-
tase, 1 £ RT buffer and 5·5 mM of MgCl2 in a final volume
of 50ml. Reverse transcription was carried out using a T3 ther-
mocycler (Biometra) with the following cycle program:
10 min at 258C; 30 min at 488C; 5 min at 958C; cycle completion
at 48C. Low-density arrays were designed online on the
Applied Biosystems website. The samples were loaded and
run on a quantitative ABI-Prism 7900HT system (Applied Bio-
systems) according to the manufacturer’s protocol. Quantifi-
cation values were normalised to the mean values of three
housekeeping genes: b-actin; glyceraldehyde-3-phosphate
dehydrogenase (GAPDH); hypoxanthine guanine phosphori-
bosyltransferase (HPRT). Based on the cycle threshold (Ct)
values obtained, a relative and normalised mRNA expression
level was determined for each gene using the DCt method.
The Ct value for each gene was corrected by the mean Ct
value of the three housekeeping genes. The results were calcu-
lated as a relative expression using the following formula:
22DC t £ K, where K is a 106 factor, and expressed as arbitrary
units. Fold increase in the expression levels of the experimental
groups was normalised to those of the negative control group.
Analysis of the bioavailable metabolites of epicatechin in
the plasma of ovalbumin-sensitised mice
Plasma (200ml) samples were analysed using a previously
reported methodology(18). Briefly, the samples were directly
loaded onto a protein precipitation and phospholipid
removal plate (Ostro; Waters Corporation). Plasma protein
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precipitation was ensured by adding 600ml of acetonitrile to
the samples and mixing the contents thoroughly with a pip-
ette. Then, the samples were filtered using a vacuum manifold
for 5 min and recuperated in a 1 ml collection plate. The
extraction procedure was enhanced by including a washing
step with 200ml of methanol. Later, the eluates were dried
to a residue at room temperature under a flow of N2. Finally,
the residue was dissolved in 100ml of 8 % acetonitrile in acidic
water. Once the residue was resuspended, (2)-epicatechin
metabolites were separated by reversed-phase ultra-
performance liquid chromatography using an Acquity UPLC
HSS C18 2·1 £ 100 mm, 1·8mm column (Waters) equipped
with a HSS C18 VanGuard pre-column (Waters) as described
previously. The standardisation and validation of the method-
ology were done by analysing calibration samples prepared
from plasma (concentration range: 0·025–5mM). The pro-
cedure followed is summarised in Table S1 (available online).
Quantification of the serum concentrations of
ovalbumin-specific IgE
The serum concentrations of OVA-specific IgE were quanti-
fied by ELISA. Plates (NUNC Maxisorp; VWR) were coated
overnight at 48C with rat anti-mouse IgE (2mg/ml; BD
Sensitisation: 20 mg OVA/mouse+10 µg cholera 
toxin/mouse through oral administration
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Fig. 1. Ability of two different polyphenol-enriched apple extracts to affect allergy symptoms in sensitised mice. (a) Ovalbumin (OVA)-induced murine model of
food allergy and timing of dietary intervention. (b) Allergy symptom scores after intervention with polyphenol-enriched apple extracts. (c) Distribution of allergy
symptom scores (scale 0–4) in the different groups (0, ; 1, ; 2, ; 3, ; 4, ), with 4 being the score indicating the severest symptom. (d) Drop in temperature
(8C) recorded in the different groups before and after the challenge. (e) Concentration of OVA-specific IgG2a (mg/ml) in the different groups. Groups are rep-
resented as negative control (Neg cont, ), positive control (Pos cont, ), apple extract A ( ) and apple extract B ( ). ** Mean value was significantly different
from that of the positive control group (P,0·01).
A. Singh et al.360
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114514000877
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:50:01, subject to the Cambridge Core terms of use, available at
Pharmingen). The wells were washed and then blocked with
PBS containing Tween and 1 % bovine serum albumin (BSA)
for 1 h at room temperature. Serially diluted sera and stan-
dard (monoclonal mouse anti-OVA; ABD Serotec) were incu-
bated for 2 h at 378C. Then, biotinylated OVA (4mg/ml; US
Biological) was added to the plates for 1 h at 378C, followed
by incubation with horseradish peroxidase (HRP) labelled
streptavidin (1:200; R&D Systems) for 30 min at 378C. The
plates were developed with a tetramethylbenzidine substrate
(KPL). The reaction was stopped with 1 M-HCl (Merck). Opti-
cal densities were measured at 450 nm. The concentrations of
OVA-specific IgE were calculated by converting the optical
density values in pg/ml using a polynomial standard curve.
Quantification of the serum concentrations of
ovalbumin-specific IgG1 and IgG2a
The serum concentrations of anti-OVA IgG1 and IgG2a were
quantified by ELISA. Briefly, microtitre plates were coated with
OVA (Sigma) (100 mg/ml) overnight at 48C. The wells were
washed with PBS containing 0·05 % Tween (Bio-Rad) and then
blocked with PBS containing 1 % BSA for 1 h at room tempera-
ture. Serially diluted standard (monoclonal mouse anti-OVA
IgG1 and monoclonal mouse anti-OVA IgG2a from Antibody
Shop; Lucerna-Chem) and sera were incubated for 2 h at 378C,
followed by incubation for 2 h with a HRP labelled goat anti-
mouse IgG1 or IgG2a antibody (1:5000; Southern Biotech; Bio-
concept). The plates were developed, read and analysed as
described above.
Quantification of the serum concentrations of
mouse mast cell protease 1
The serum concentrations of mouse mast cell protease 1
(mMCP-1) were quantified by ELISA (Moredun Scientific)
according to the manufacturer’s instructions. The concen-
trations of mMCP-1 were calculated by converting the optical
density values in pg/ml using a polynomial standard curve.
Isolation and culture of mesenteric lymph node cells
Mesenteric lymph nodes were homogenised using a syringe
plunger in a cell strainer (BD Falcon; Milian). The cells were
centrifuged and washed two times with Roswell Park
Memorial Institute (RPMI) medium (Sigma) supplemented
with 10 % fetal bovine serum (Bioconcept), 1 % L-glutamine
(Sigma), 1 % penicillin/streptomycin (Sigma) and 0·1 % genta-
micin (Sigma), and 50 mM-b-mercaptoethanol (Sigma). The
cells (3E5 cells/well) were cultured in a ninety-six-well flat-
bottom plate (Corning, Milian) in the absence or presence of
OVA (1000mg/ml). After 72 h of culture, the plates (including
the supernatant and cells) were frozen at 2208C.
Determination of the concentrations of cytokines in
mesenteric lymph node cultures
The concentrations of cytokines in cell-culture supernatants
were determined with an electrochemiluminescence-based
multiplex assay using the mouse TH1/TH2 4-Plex Kit (Meso
Scale Discovery) according to the manufacturer’s instructions.
Statistical analyses
All the outcome measures were analysed using a non-para-
metric approach. Kruskal–Wallis tests were used initially,
followed by the Mann–Whitney–Wilcoxon tests for the
group comparisons of interest (mainly tested ingredients v.
positive control as well as positive control v. negative control).
For each comparison between two groups, only raw Wilcoxon
P values are reported, and results are considered significant if
P value is #0·5.
Results
Ability of two different polyphenol-enriched
apple extracts to modulate allergy symptoms in an
ovalbumin-induced murine model of food allergy
We evaluated two different polyphenol-enriched apple
extracts to assess their in vivo anti-allergic effect. The mice
were sensitised via the oral route to the allergen OVA and cho-
lera toxin given as an adjuvant. The polyphenol-enriched
apple extracts (1 % in the diet) were administered to the
sensitised mice for 8 d to determine whether the symptoms
would be attenuated upon a challenge with a high dose of
OVA (Fig. 1(a)). As shown in Fig. 1(b), the allergy symptom
scores of the positive control group were significantly
increased upon exposure to the OVA challenge when com-
pared with those of the negative control group (P¼0·002).
The allergy symptom scores of the two groups of sensitised
mice fed diets containing polyphenol-enriched apple extracts
were significantly different from those of the positive control
group. No significant effect was observed on the allergy symp-
tom scores of the group treated with polyphenol-enriched
apple extract A (P¼0·65) when compared with those of the
positive control group, whereas the allergy symptom scores
of the group treated with polyphenol-enriched apple extract
B were significantly decreased (P¼0·01) when compared
with those of the positive control group. The distribution of
allergy symptom scores based on their magnitudes across
the different groups of mice is shown in Fig. 1(c). Both the
positive control group and the apple extract A-treated group
had a similar distribution, i.e. a greater percentage of mice
with high allergy symptom scores (between 2 and 4), whereas
the apple extract B-treated group had a higher percentage of
mice with lower allergy symptom scores (between 0 and 1).
The drop in temperature (measured before and after the chal-
lenge) was more evident in the positive control group and the
apple extract A-treated group, whereas differences in tempera-
ture were minimal in the apple extract B-treated group
(Fig. 1(d)). Among the circulating allergen-specific Ig in the
plasma of the different groups of mice, interestingly, an
increase in the concentrations of OVA-specific IgG2a was
observed after treatment with apple extract B (P¼0·01;
Fig. 1(e)). No significant changes in the concentrations of
other specific Ig (OVA-specific IgE and OVA-specific IgG1)
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or mMCP-1 were observed in the experimental groups (data
not shown).
Polyphenol composition analysis of apple extracts A and B
We analysed two apple extracts obtained from different sup-
pliers and administered them in vivo to the OVA food allergy
model to determine which bioactive factors contributed to the
differential effect in vivo on allergy symptoms, as both were
essentially advertised to be polyphenol-enriched extracts
(Table 1). The analysis revealed the extracts to have similar
levels of energy, fat and moisture. Interestingly, when the
polyphenol concentrations of the two extracts were quanti-
fied, extract B was found to be highly enriched with flavanols,
especially epicatechin (285·10 (SE 14·78) mg/g) and its
polymeric compounds, whereas extract A had minimal con-
centrations of this class of polyphenols (0·61 (SE 0·08) mg/g).
Extract A was found to be enriched with other classes of
polyphenols such as phloridzin (5 % by weight equivalent to
50 mg/g), while extract B had minimal concentrations of
polyphenol classes other than flavanols.
Effect of oral administration of purified epicatechin and
epicatechin-enriched cocoa extract on allergy symptoms in
ovalbumin-sensitised mice
As the polyphenol-enriched apple extract that exhibited a sig-
nificant anti-allergic effect had high concentrations of epicate-
chin, we investigated the effect of oral administration of
purified epicatechin and another well-known epicatechin-
enriched plant extract – cocoa extract – on allergy symptom
scores in sensitised mice. In the first experiment (Fig. 2(a)),
we administered either epicatechin (1 % included in the diet)
or an epicatechin-enriched cocoa extract (6 % included in
the diet, adjusted by the amount of epicatechin present as
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Fig. 2. Effect of epicatechin on allergy symptom scores. (a) Allergy symptom scores after dietary intervention with 1 % epicatechin (Epi, ) or a cocoa extract
enriched with epicatechin ( ) in comparison with those of the negative control (Neg cont, ) and positive control (Pos cont, ) groups. (b) Distribution of allergy
symptom scores (scale 0–4) in the different groups (0, ; 1, ; 2, ; 3, ; 4, ), with 4 being the score indicating the severest symptom. (c) Dose-dependent
effect of epicatechin included at three different doses (0·01 % Epi, 0·3 % Epi and 1 % Epi) in the diet on allergy symptoms. (d) Distribution of allergy symptom
scores (scale 0–3) in the different groups (0, ; 1, ; 2, ; 3, ), with 3 being the score indicating the severest symptom. Mean value was significantly different
from that of the positive control group: *P¼0·04, **P¼0·03, ***P¼0·007.
Table 1. Polyphenol composition of the apple extracts
(Median values with their standard errors)
Extract A Extract B
Composition Median SE Median SE
Polyphenols (mg/g)
Epicatechin 0·61 0·08 285·10 14·78
Procyanidin B2 0·67 0·03 53·88 3·35
Catechin 0·15 0·01 8·27 0·49
Phloridzin 50·0 5·0 12·0 3·0
A. Singh et al.362
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114514000877
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:50:01, subject to the Cambridge Core terms of use, available at
provided by the supplier) to the sensitised mice for 8 d. Com-
pared with the positive control group, which had significantly
increased allergy symptom scores when compared with the
negative control group (P¼0·001), the 1 % epicatechin-treated
group had significantly lower allergy symptom scores
(P¼0·007). The same pattern was observed in mice treated
with the epicatechin-enriched cocoa extract when compared
with the positive control group (P¼0·04). The positive control
group had an increased proportion of mice with very high
allergy symptom scores ($2) in comparison with the group
treated with epicatechin 1 % or epicatechin-enriched cocoa
extract (Fig. 2(b)). We subsequently investigated whether the
anti-allergic effect of epicatechin was dose dependent. Epica-
techin was included at three different doses (1, 0·3 and 0·01 %)
in the diet of sensitised mice. The results of this experiment
are shown in Fig. 2(c). Compared with those of the negative
control group, the allergy symptom scores of the positive
control group were significantly increased (P¼0·01); adminis-
tration of epicatechin at low doses (0·01 %) had no effect on
the allergy symptom scores of this group (P¼0·75) when
compared with those of the positive control group. However,
the allergy symptom scores of the 0·3 and 1 % epicatechin-
treated groups were significantly decreased (P¼0·1 in the
0·3 % group and P¼0·03 in the 1 % group) when compared
with those of the positive control group. The positive control
group and the 0·01 % epicatechin-treated group had a greater
percentage of mice with high allergy symptom scores
(Fig. 2(d); 60 % or more animals in these groups had an allergy
symptom score $2 upon a challenge with OVA) compared
with the 0·3 and 1 % epicatechin-treated groups, which had
a lower percentage of mice with high scores (#25 % of the
animals in the group).
Effect of oral administration of epicatechin on specific Ig
(ovalbumin-specific IgE, IgG1 and IgG2a) concentrations
and effector cell responses (mouse mast cell protease 1
and cytokines after mesenteric lymph node stimulation) in
ovalbumin-sensitised mice
Significant differences were observed between the negative
control group and the positive control group with regard to
the concentrations of OVA-specific Ig, with the latter group
having higher concentrations. The positive control group
had higher concentrations (median values with their standard
errors) of OVA-specific IgE (144·09 (SE 70·27) ng/ml) than the
0·3 % epicatechin-treated group (89·11 (SE 34·88) ng/ml) and
the 1 % epicatechin-treated group (26·28 (SE 13·31) ng/ml).
The concentrations of OVA-specific IgG2a of the epicate-
chin-treated groups were higher (417·87 (SE 146·16) ng/ml in
the 0·3 % group and 916·41 (SE 364·49) ng/ml in the 1 %
group) than those of the positive control group (311·33 (SE
148·73) ng/ml). No statistically significant differences were
observed in the concentrations of OVA-specific IgG1, mMCP-
1 or cytokines between the groups after the stimulation of
mesenteric lymph nodes (Tables 2 and 3).
Effect of oral administration of epicatechin on gene
expression (cytokines and T-cell function-regulating
transcription factors) in the small intestine of
ovalbumin-sensitised mice
To further elucidate the effect of oral administration of epica-
techin at the site of local inflammation, we determined the
mRNA expression levels of various genes involved in T-cell-
mediated immune responses in the ileum by real-time PCR.
The gene expression levels of T-helper (Th)-1 cell (IL-12a)
and Th-2 cell (IL-13) cytokines and transcription factors
(T-box transcription factor 21 (T-bet) and GATA-binding protein
Table 2. Concentrations of specific immunoglobulins and mouse mast cell protease 1 (mMCP-1) in ovalbumin (OVA)-
sensitised mice
(Median values with their standard errors)
Negative control Positive control 0·3 % Epicatechin 1 % Epicatechin
Measurements (ng/ml) Median SE Median SE Median SE Median SE
OVA-specific IgE 0·0 144·09 70·27 89·11 34·88 26·28 13·31
OVA-specific IgG1 0·0 164·3 45·4 43·08 22·12 66·13 24·89
OVA-specific IgG2a 0·0 311·33 148·73 417·87 146·16 916·41 364·49
mMCP-1 13·55 4·09 292·68 65·20 187·06 50·06 180·67 62·14
Table 3. Concentrations of cytokines in ovalbumin-stimulated mesentric lymph node cells
(Median values with their standard errors)
Negative control Positive control 0·3 % Epicatechin 1 % Epicatechin
Measurements (pg/ml) Median SE Median SE Median SE Median SE
IL-4 0·26 0·32 7·53 2·11 9·02 2·62 7·49 1·87
IL-5 94·72 13·87 154·32 23·27 168·49 32·98 114·31 25·38
IL-10 5·31 1·78 21·32 5·92 18·94 9·19 26·22 8·67
IFN-g 523·01 205·08 781·31 182·02 706·27 222·54 752·54 164·61
IFN-g, interferon-g.
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3 (GATA-3)) that, respectively, regulate the Th-1 and Th-2 cell
responses were investigated in the ileum after the adminis-
tration of epicatechin along with those of other relevant
immune genes (IL-10, IL-17A and IL-22). The positive control
group exhibited higher relative expression of both Th-1 and
Th-2 cell-related cytokine genes in the ileum in comparison
with the negative control group. The expression of GATA-3
in the 0·3 % epicatechin-treated group was significantly
affected when compared with that in the positive control
group (Fig. 3(a); P¼0·07), whereas the expression of T-bet
in the 1 % epicatechin-treated group was significantly lower
(Fig. 3(b); P¼0·03). The 1 % epicatechin-treated group also
exhibited lower relative gene expression of both the allergy-
related Th-2 cell-related cytokine IL-13 (Fig. 3(c); P¼0·1)
when compared with the positive control group and the Th-
1 cell-related cytokine IL-12a (Fig. 3(d); P¼0·07). The
expression of other genes investigated, such as IL-10
(Fig. 3(e)) and IL-17 (data not shown), was not affected
after treatment with epicatechin in the sensitised mice. Inter-
estingly, a dose-dependent increase in the expression of
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Fig. 3. Effect of epicatechin on T-helper (Th)-1 and Th-2 cell-related cytokine gene expression in the ileum. Genes that were evaluated were (a) GATA-binding
protein 3 (GATA-3), (b) T-bet, (c) IL-13, (d) IL-12a, (e) IL-10 and (f) IL-22. Groups are represented as negative control (Neg cont, ), positive control (Pos cont,
), 0·01 % epicatechin (Epi, ), 0·3 % Epi ( ) and 1 % Epi ( ). * Mean value was significantly different from that of the positive control group (P¼0·003).
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IL-22 in the ileum of the epicatechin-treated groups was
observed (Fig. 3(f)), but it was only suggestive, as it was not
statistically significant.
Epicatechin metabolites present in the plasma of allergic
mice and relationship of bioavailable metabolite
concentrations with allergy symptom scores
We hypothesised that the anti-allergic effect of epicatechin
could be due to a systemic effect after its oral administration.
To address this hypothesis, we aimed to correlate the anti-
allergic effect observed with epicatechin bioavailability. After
oral absorption, epicatechin is rapidly transformed into its
conjugated metabolites. We first validated our previously
reported methodology for detecting epicatechin metabolites
in mouse plasma (Table S1, available online). Bioavailable
metabolites detected in mouse plasma were distributed into
three main classes, namely glucuronides, methylated glucuro-
nides and sulphated metabolites, with the 40-O-glucuronide
and 70-O-glucuronide metabolites being the major classes of
circulating compounds in mice (Fig. 4(a)). Interestingly, the
epicatechin metabolite profile of mice significantly differs
from that previously found in human plasma(18). Due to the
experimental protocol, animals in the food allergy model
could have different amounts of epicatechin in the plasma
during the experiment. Next, we investigated whether the
concentrations of total epicatechin metabolites in the plasma
of allergic mice had any relationship with the intensity of
allergy symptoms after the OVA challenge in sensitised mice.
In Fig. 4(b), the concentrations of the detected bioavailable
epicatechin metabolites in the different groups of allergic
mice, i.e. treated, respectively, with 1, 0·3 and 0·01 % of
epicatechin included in the diet, are shown. The 1 %
epicatechin-treated group had the highest concentrations of
bioavailable epicatechin metabolites in comparison with the
0·3 and 0·01 % epicatechin-treated groups. On comparison of
the concentrations of the total epicatechin metabolites in
each allergic mouse with their corresponding allergy symptom
scores (n 43 mice, all mice from the 0·01, 0·3 and 1 %
epicatechin-treated groups were pooled), mice that had
lower allergy symptom scores (0–1) were found to have
higher concentrations of bioavailable epicatechin metabolites
in their plasma than those having higher allergy symptom
scores (2–3) and lower concentrations of bioavailable
epicatechin metabolites (Fig. 4(c)).
Discussion
We and others have previously reported on the beneficial
effect of polyphenol-enriched plant extracts in experimental
animal models of allergy(12,16,17). A few clinical trials carried
out using polyphenol-containing apple extracts have also
shown that their consumption leads to the alleviation of
allergy symptoms such as runny nose and nasal congestion
in subjects suffering from allergic rhinitis(13,14). Polyphenols
are a heterogeneous class of bioactive compounds that are
abundantly present as multiple classes across several plant
and fruit species(7). Currently, there is no necessary dietary
intake recommendation for polyphenols, although it is
estimated that the combined intake from various plant and
fruit resources totals about 1 g/d in certain diets across the
world(26,27). In plant extracts, numerous classes of poly-
phenols with a potential to exert beneficial effects on health,
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Fig. 4. Concentrations of (2 )-epicatechin metabolites and their relationship
with allergy symptom scores. (a) Panel of various (2 )-epicatechin metab-
olites in the epicatechin-treated mice. (b) Total (2 )-epicatechin metabolite
concentration (nM) measured in the plasma of treated mice in the three differ-
ent groups: 1 % epicatechin (Epi); 0·3 % Epi; 0·01 % Epi. (b) Correlation
between total (2)-epicatechin metabolite concentration (nM) measured in the
plasma of treated mice (n 43 mice) and allergy symptom scores recorded in
individual animals.
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e.g. with respect to immune disorders, have been described
previously(28,29). We found that the two polyphenol-enriched
apple extracts (.40 % enriched with polyphenols) evaluated
in the present study had different in vivo efficacy to modulate
allergy symptoms.
Herein, we report the discovery of epicatechin as one of the
key bioactive polyphenols within the matrices of plant extracts
that exhibit a beneficial anti-allergic effect. Although the oral
administration of epicatechin attenuated allergy symptoms
in a dose-dependent manner, polyphenol-enriched extracts
with minimal concentrations of epicatechin had no impact
on allergy symptoms. These findings are novel and suggest
that foods rich in epicatechin, such as apples and cocoa,
may exert an anti-allergic effect in individuals suffering from
allergic disorders. Alternatively, pharmaceutical-grade prep-
arations specifically containing epicatechin at an optimal
dosage could also bring relief to those suffering from allergy
symptoms.
We have previously observed in our mouse model that
mucosal allergen challenge via the oral route following sensit-
isation results in the local up-regulation of immune cytokines
in the ileum(24). With this knowledge, we next investigated
whether purified epicatechin delivered via the diet to sensi-
tised mice has an immunological effect at the site of local
inflammation, i.e. the ileum of allergic mice. Epicatechin at
the doses of 0·3 and 1 % had an impact on the expression of
both Th-1 and Th-2 cell-related cytokine genes. The relative
gene expression of IL-13, IL-12a and T-bet in the 1 % epicate-
chin-treated group was decreased when compared with that
in the positive control group, while the relative gene
expression of GATA-3 was significantly affected in the 0·3 %
epicatechin-treated group. These findings, which correlate
well with the observed effect of epicatechin treatment on clini-
cal symptoms, are reflective, in general, of the potential effect
that epicatechin can have on both the Th-1 and Th-2 arms of
the adaptive immune response. It can be argued that a
decrease in the gene expression of T-bet locally at the site of
inflammation may further bias the Th-2 cell-driven response
observed in our model; however, the adaptive immune
response to a foreign antigen involves a complex interplay
of many cell- and tissue-related players. The T-helper cell
response, as we know today, is simply not just restricted to
a Th-1 or a Th-2 bias, but can exist in many phenotypes
(Th-17, regulatory T cell (Treg), Th-9 and Th-22), and this
is highly dependent on the context of the inflammatory
response. In line with our observations are the results of pre-
vious studies demonstrating a beneficial effect of apple
extracts enriched with polyphenols on both Th-1(11) and
Th-2 diseases(16,17). Interestingly, we also observed a dose-
dependent up-regulation of IL-22 relative gene expression
in the ileum after the administration of epicatechin. IL-22
is an immune-modulatory cytokine that has recently been
described to play an important role at mucosal surfaces(30).
IL-22 is thought to be secreted by innate lymphoid-like cells
that line mucosal surfaces and has been shown to inhibit
inflammation in a murine model of allergic airway disease(31).
It has recently been reported in the literature that one of the
signalling pathways implicated in the up-regulation of IL-22
gene expression involves the aryl-hydrocarbon receptor, for
which flavonoids and other dietary polyphenols are the
well-known ligands(32). Our observations related to IL-22 are
preliminary in nature, but warrant future investigations into
the role of IL-22 and aryl-hydrocarbon receptor following
the administration of epicatechin.
A majority of the absorbed native polyphenols are exten-
sively converted into conjugated metabolites and circulate
within different systemic compartments(33–35). The beneficial
anti-allergic effect can probably be the result of the generation
of these metabolites in vivo within the host. Epicatechin
metabolites and their kinetics of appearance in the systemic
circulation have been well studied in human subjects(18,34,36).
However, no previous studies have reported the detection or a
profile of these metabolites in mice. We established a robust
detection assay to detect in vivo epicatechin metabolites in
the plasma of mice. The extensive profile of epicatechin
metabolites in mice comprises glucuronides and sulphated
and methylated metabolites. When we matched the bioavail-
able epicatechin metabolite concentrations measured in the
plasma of allergic mice with individual allergy symptom
scores of the epicatechin-treated mice, we found that mice
that had lower allergy symptom scores had increased concen-
trations of bioavailable metabolites of epicatechin. This is an
intriguing and relevant finding, which suggests that bioavail-
ability measurements should be taken into consideration in
experimental settings where the bioefficacy of a dietary inter-
vention is investigated to better understand the variable
responses in a group of experimental subjects or animals.
In summary, we report novel results that identify epicate-
chin as an anti-allergic agent. Epicatechin when administered
at higher doses or epicatechin-enriched polyphenol extracts
administered orally by inclusion in diet suppress allergy symp-
toms. This effect may result from direct signalling to host
receptors leading to a local effect at the site of inflammation
and/or from a systemic effect mediated by the epicatechin-
derived metabolites; this does not exclude the possibility
that other major bioactive components, i.e. other polyphenols
such as catechin, procyanidin B1 and procyanidin B2 within
the matrix of apple or cocoa extracts, could play an important
role as well and have an impact on allergic manifestations.
Future studies should investigate the role of some of these
components within the matrix and address the cellular
immune mechanisms and signalling pathways involved in
the described anti-allergic effect. We also established a meta-
bolite profile that allows systemic tracking of the therapeutic
effect of epicatechin. These findings remain to be investigated
in translational settings (we have begun preliminary
investigations into the immunological profile of epicatechin
metabolites using human ex vivo assays; Fig. S1, available
online) and in human clinical trials to ascertain the anti-
allergic effect of epicatechin.
Supplementary material
To view supplementary material for this article, please visit
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